(-0.21%) 5 136.25 points
(-0.15%) 38 503 points
(-0.21%) 17 868 points
(0.40%) $82.96
(2.41%) $2.08
(-1.43%) $2 323.90
(-2.87%) $26.87
(-1.56%) $946.50
(-0.02%) $0.932
(0.33%) $11.02
(0.12%) $0.797
(0.06%) $93.36
6.39% $ 14.81
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
Dzisiejszy wolumen | 13 521.00 |
Średni wolumen | 12 441.00 |
Kapitalizacja rynkowa | 32.80M |
EPS | $-0.000220 ( 2023-06-29 ) |
Last Dividend | $0.195 ( 2023-12-14 ) |
Next Dividend | $0 ( N/A ) |
P/E | -17.16 |
ATR14 | $0.250 (1.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Klein Dov | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 51 transactions |
Buy: 13 110 352 | Sell: 133 334 |
Fortress Biotech Inc. Korelacja
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fortress Biotech Inc. Finanse
Annual | 2023 |
Przychody: | $84.51M |
Zysk brutto: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
Przychody: | $84.51M |
Zysk brutto: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
Przychody: | $75.74M |
Zysk brutto: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
Przychody: | $68.79M |
Zysk brutto: | $36.71M (53.36 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Fortress Biotech Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.390 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.586 | 2018-03-14 |
Last Dividend | $0.195 | 2023-12-14 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-31 | |
Next Payout Date | N/A | |
# dividends | 51 | -- |
Total Paid Out | $13.86 | -- |
Avg. Dividend % Per Year | 7.56% | -- |
Score | 5.87 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 1.121 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $2.34 | 10.60% |
2019 | $2.34 | 14.50% |
2020 | $2.34 | 11.40% |
2021 | $2.34 | 12.10% |
2022 | $2.15 | 8.20% |
2023 | $2.34 | 13.30% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.724 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.365 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.56 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.143 | -1.000 | -1.432 | 1.432 | [0 - 1] |
currentRatioTTM | 1.378 | 0.800 | 8.11 | 6.49 | [1 - 3] |
quickRatioTTM | 1.134 | 0.800 | 8.03 | 6.43 | [0.8 - 2.5] |
cashRatioTTM | 0.953 | 1.500 | 5.82 | 8.72 | [0.2 - 2] |
debtRatioTTM | 0.420 | -1.500 | 3.01 | -4.51 | [0 - 0.6] |
interestCoverageTTM | -11.92 | 1.000 | -5.53 | -5.53 | [3 - 30] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -4.28 | -8.57 | [0 - 20] |
debtEquityRatioTTM | 3.12 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.680 | 1.000 | 1.999 | 1.999 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.681 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.824 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.504 | 0.800 | 9.97 | 7.98 | [0.5 - 2] |
Total Score | -2.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.424 | 1.000 | -0.144 | 0 | [1 - 100] |
returnOnEquityTTM | -2.56 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -2.86 | -8.57 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
payoutRatioTTM | -0.143 | 1.500 | -1.432 | 1.432 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.517 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.87 |
Fortress Biotech Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej